Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Cancer Research

• Publication date

  1987-03-15

• Fields of study

  Medicine

• Identifiers
  PMID 3815369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of VP16-213 given by different administration methods

  2004cited by this paper
• Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

  1986cited by this paper
• Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.

  1985cited by this paper
• Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents.

  1985cited by this paper
• VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

  1985cited by this paper
• The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.

  1984cited by this paper
• Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.

  1984cited by this paper
• Totally implantable system for peritoneal access.

  1984cited by this paper
• The use of intraperitoneal chemotherapy in the treatment of ovarian cancer

  1984cited by this paper
• Chemotherapy of ovarian cancer.

  1984cited by this paper
• High-performance liquid chromatography of cisplatin.

  1983cited by this paper
• Etoposide salvage therapy for refractory germ cell tumors: an update.

  1982cited by this paper
• Intraperitoneal cisplatin with systemic thiosulfate protection.

  1982influential reference
• High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.

  1981cited by this paper
• Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

  1981cited by this paper
• Epithelial carcinoma of the ovary: current strategies.

  1981cited by this paper
• Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

  1980cited by this paper
• Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.

  1980cited by this paper
• cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

  1979cited by this paper
• Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.

  1979cited by this paper
• Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

  1978cited by this paper
• Chemotherapy of ovarian cancer.

  1978cited by this paper
• Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

  1975cited by this paper

• Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer

  2025cites this paper
• Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines

  2025cites this paper
• Impact of Institutional Standard Operating Procedures on Perioperative Outcomes in Patients Undergoing Cytoreductive Surgery with and without HIPEC: A Comparative Analysis in Ovary Cancer

  2025influential citation
• Prospects of the Surgical Management of Colorectal Peritoneal Metastasis.

  2024cites this paper
• Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.

  2023cites this paper
• Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

  2023cites this paper
• Better effect of intrapleural perfusion with hyperthermic chemotherapy by video‐assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity

  2021cites this paper
• The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer

  2020cites this paper
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

  2020cites this paper
• Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

  2020cites this paper
• Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study

  2019cites this paper
• Incisional Hernia in Oncologic Surgery

  2019cites this paper
• Modeling of drug delivery and transport during intraperitoneal chemotherapy

  2019cites this paper
• Robotic Assisted Hernia Repair: Current Practice

  2019cites this paper
• Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial

  2018cites this paper
• Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review

  2018cites this paper
• Colorectal and appendiceal peritoneal metastases : From population studies to genetics

  2018cites this paper
• Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis

  2018cites this paper
• Intestinal toxicity evaluation of long‐circulating and pH‐sensitive liposomes loaded with cisplatin

  2017cites this paper
• Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.

  2017cites this paper
• Intraperitoneal immunotherapy: historical perspectives and modern therapy

  2016cites this paper
• Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.

  2016cites this paper
• Sonoporation: Applications for Cancer Therapy.

  2016cites this paper
• Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer

  2015cites this paper
• Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors.

  2014cites this paper
• Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

  2014cites this paper
• Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

  2013cites this paper
• Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.

  2013cites this paper
• Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft

  2012cites this paper
• Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics

  2012cites this paper
• Intraperitoneal therapy for peritoneal cancer.

  2010cites this paper
• Intraperitoneal chemotherapy for ovarian cancer

  2010cites this paper
• Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery

  2010cites this paper
• CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.

  2010cites this paper
• Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer

  2008cites this paper
• Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer

  2008cites this paper
• Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature

  2007cites this paper
• Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside.

  2007cites this paper
• Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel

  2007cites this paper
• Principles and practice of intraperitoneal chemotherapy for ovarian cancer

  2006cites this paper
• Phase I Pharmacokinetic Study of Intraperitoneal Etoposide 1

  2006cites this paper
• Intraperitoneal chemotherapy in ovarian cancer: who and when?

  2005cites this paper
• Administered Intrapleurally in Patients with Malignant Pleural Effusions 1

  2005cites this paper
• Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

  2005cites this paper
• Innovative therapies: intraoperative intracavitary chemotherapy.

  2004cites this paper
• Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach

  2004cites this paper
• Intraarticular and intraperitoneal administration of etoposide in haematological malignancy

  2004cites this paper
• Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis

  2004cites this paper
• Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread.

  2004cites this paper
• Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy

  2003cites this paper
• Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

  2003cites this paper
• Biodegradable paclitaxel-loaded PLGA microspheres for regional treatment of peritoneal cancers.

  2003influential citation
• A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma.

  2001cites this paper
• Intraperitoneal chemotherapy in ovarian cancer.

  2000cites this paper
• Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis

  1999cites this paper
• Usefulness of Intraperitoneal Administration of Cisplatin Using a Reservoir for Advanced Gastric Cancer Complicated by Peritoneal Dissemination

  1999cites this paper
• 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study.

  1999cites this paper
• Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice

  1998cites this paper
• Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.

  1997cites this paper
• Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion

  1996cites this paper
• Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.

  1996cites this paper
• Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.

  1995cites this paper
• Successful chemoradiation therapy for high-grade skull base chondrosarcoma in a child

  1995cites this paper
• A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

  1994cites this paper
• Pharmacokinetic Aspects of Etoposide Therapy — A Review

  1994cites this paper
• A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies

  1994cites this paper
• Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.

  1994cites this paper
• Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement.

  1994cites this paper
• Pharmacokinetics of intrapleural recombinant interleukin‐2 in immunotherapy for malignant pleural effusion

  1994cites this paper
• High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.

  1993cites this paper
• A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.

  1993cites this paper
• Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide.

  1993cites this paper
• Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity.

  1993cites this paper
• Pharmacokinetic principles of locoregional chemotherapy.

  1993cites this paper
• A phase 2 study of cisplatin in patients with hepatocellular carcinoma.

  1993cites this paper
• Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer.

  1993cites this paper
• Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.

  1993cites this paper
• Intraperitoneal therapy in the management of patients with ovarian cancer.

  1992cites this paper
• Ovarian cancer, Part II: Treatment.

  1992cites this paper
• Intraperitoneal Therapy in the Management of Patients with Oyarian Cancer

  1992cites this paper
• Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.

  1992cites this paper
• Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?

  1992cites this paper
• Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.

  1991cites this paper
• Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.

  1991cites this paper
• Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

  1991cites this paper
• Phase I pharmacokinetic study of intraperitoneal etoposide.

  1991cites this paper
• A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.

  1991cites this paper
• Pharmacologic Study of Etoposide and Cisplatin by the Intraperitoneal Route

  1991cites this paper
• Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.

  1991cites this paper
• Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

  1990cites this paper
• Ovarian cancer, part II: Treatment

  1990cites this paper
• The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.

  1990cites this paper
• Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.

  1990cites this paper
• A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.

  1990cites this paper
• A review: intraperitoneal cisplatin in the management of patients with ovarian cancer.

  1990cites this paper
• Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).

  1989cites this paper
• Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.

  1989cites this paper
• Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.

  1989cites this paper
• Dipyridamole enhancement of etoposide sensitivity.

  1989cites this paper
• Intraperitoneal therapy in the management of ovarian carcinoma.

  1989cites this paper